<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00215722</url>
  </required_header>
  <id_info>
    <org_study_id>GICR-P003</org_study_id>
    <nct_id>NCT00215722</nct_id>
  </id_info>
  <brief_title>XELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo de Investigacao do Cancro Digestivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo de Investigacao do Cancro Digestivo</source>
  <brief_summary>
    <textblock>
      The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented&#xD;
      at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.&#xD;
&#xD;
      This study is aimed at establishing the efficacy and safety of the combination&#xD;
      cetuximab/XELOX as first line therapy in patients with MCRC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase II trials with XELOX, demonstrated that is a highly effective first-line treatment&#xD;
      for metastatic colorectal cancer, with response rates similar to the regimens with&#xD;
      oxaliplatin and infusional 5-FU/LV (FOLFOX), but more convenient and likely to be preferred&#xD;
      by both patients and health care providers.&#xD;
&#xD;
      Cetuximab has a significant anti-cancer activity in the setting of chemo-resistant disease&#xD;
      which suggests that a much greater degree of benefit may ensue when it is used at an earlier&#xD;
      stage of the disease course.&#xD;
&#xD;
      The first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented&#xD;
      at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination.&#xD;
&#xD;
      This study is aimed at establishing the efficacy and safety of the combination&#xD;
      cetuximab/XELOX as first line therapy in patients with MCRC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date type="Anticipated">July 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Efficacy of the combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy based on the overall response rate (ORR) according to the RECIST criteria.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the Safety parameters of combination treatment (cetuximab plus capecitabine and oxaliplatin) as first-line therapy analyzing the frequency, severity, duration and relationship of adverse events using the NCI CTCAE, version 3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumour progression (TTP)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival time (OS)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Quality of Life</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed written informed consent, prior any study-specific procedures&#xD;
&#xD;
          -  Male or female &gt; = 18 years of age&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the colon or rectum with metastatic disease&#xD;
             not eligible for surgery with curative intent - in case of a unique metastatic lesion&#xD;
             this should be confirmed by biopsy&#xD;
&#xD;
          -  ECOG performance status &lt; 1 at study entry&#xD;
&#xD;
          -  Immunohistochemical evidence of EGFR expression on tumour tissue&#xD;
&#xD;
          -  Presence of at least one unidimensional measurable lesion with a diameter &gt; 20mm by&#xD;
             conventional CT scan or MRI, and 10mm by spiral CT scan, according to the RECIST&#xD;
             criteria (Index lesion(s) must not lie within an irradiated area)&#xD;
&#xD;
          -  Have not received any Chemotherapy regimen for metastatic disease&#xD;
&#xD;
          -  Life expectancy of &gt; 3 months&#xD;
&#xD;
          -  Neutrophils &gt; = 1.5 x 109/L, platelet count &gt; = 100 x 109/L, and haemoglobin &gt; = 9&#xD;
             g/dL.&#xD;
&#xD;
          -  Bilirubin level either normal or 1.5 x ULN&#xD;
&#xD;
          -  ASAT and ALAT &lt; = 2.5 x ULN (&lt; = 5 x ULN in case of liver metastasis)&#xD;
&#xD;
          -  Alkaline phosphatase &lt; = 2.5 x ULN or &lt; = 5 x ULN in case of liver metastasis or &lt; =&#xD;
             10 x ULN in case of bone metastases&#xD;
&#xD;
          -  Serum creatinine &lt; = 1.5 x ULN or CrCl &gt; 50 ml/min (Cockroft and Gault formula)&#xD;
&#xD;
          -  Negative Pregnancy test within one week before treatment start, if applicable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous chemotherapy for metastatic CRC or adjuvant therapy with oxaliplatin or&#xD;
             irinotecan.&#xD;
&#xD;
          -  Adjuvant or neo-adjuvant therapy with 5 FU or derivatives is allowed if the&#xD;
             chemotherapy treatment free interval is &gt; 6 months and the patient have not progressed&#xD;
             during treatment&#xD;
&#xD;
          -  Surgery (excluding diagnostic biopsy) or irradiation within 4 weeks prior to study&#xD;
             entry&#xD;
&#xD;
          -  Prior radiotherapy is permitted if it was not administered to target lesions selected&#xD;
             for this study&#xD;
&#xD;
          -  Concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not&#xD;
             indicated in the study protocol&#xD;
&#xD;
          -  Any investigational agent(s) within 4 weeks prior to entry&#xD;
&#xD;
          -  Previous exposure to EGFR-pathway targeting therapy&#xD;
&#xD;
          -  History of evidence upon physical examination of CNS disease (e.g. primary brain&#xD;
             tumour, seizure not controlled with standard therapy, any brain metastasis or history&#xD;
             of stroke)&#xD;
&#xD;
          -  Clinically relevant coronary artery disease or a history of a myocardial infarction&#xD;
             within the last 12 months&#xD;
&#xD;
          -  Serious uncontrolled intercurrent infections, or other serious uncontrolled&#xD;
             concomitant disease&#xD;
&#xD;
          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease&#xD;
&#xD;
          -  Pre-existing neuropathy &gt; grade 1&#xD;
&#xD;
          -  Known grade 3 or 4 allergic reaction to any of the components of the treatment.&#xD;
&#xD;
          -  Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of&#xD;
             the cervix. (Patients with a previous malignancy but without evidence of disease for &gt;&#xD;
             = 5 years will be allowed to enter the trial)&#xD;
&#xD;
          -  Known drug abuse/ alcohol abuse&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity&#xD;
&#xD;
          -  Medical or psychological condition which in the opinion of the investigator would not&#xD;
             permit the patient to complete the study or sign meaningful informed consent&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Sexually active males and females (of childbearing potential) unwilling to practice&#xD;
             contraception during the study&#xD;
&#xD;
          -  Lack of physical integrity of the upper gastrointestinal tract or those who have&#xD;
             malabsorption syndrome&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase deficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evaristo Sanches, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo de Investigação do Cancro Digestivo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sérgio Barroso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grupo de Investigação do Cancro Digestivo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Garcia de Orta</name>
      <address>
        <city>Almada</city>
        <zip>2800</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Distrital do Barreiro</name>
      <address>
        <city>Barreiro</city>
        <zip>2830</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Distrital de Beja</name>
      <address>
        <city>Beja</city>
        <zip>7800-309</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de São Marcos</name>
      <address>
        <city>Braga</city>
        <zip>4700</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitais da Universidade de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPO - Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar do Funchal</name>
      <address>
        <city>Funchal</city>
        <zip>9000-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pedro Hispano</name>
      <address>
        <city>Matosinhos</city>
        <zip>4454-509</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital do Divino Espírito Santo</name>
      <address>
        <city>Ponta Delgada</city>
        <zip>9500-370</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPO - Porto</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>April 5, 2007</last_update_submitted>
  <last_update_submitted_qc>April 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

